Modeling of chitosan modified PLGA atorvastatin-curcumin conjugate (AT-CU) nanoparticles, overcoming the barriers associated with PLGA: An approach for better management of atherosclerosis

Dash, Rasmita; Yadav, Madhulika; Biswal, Jyotirmaya; Chandra, Anshuman; Goel, Vijay K.; Sharma, Tripti; Prusty, Shakti Ketan; Mohapatra, Sujata

doi:10.1016/j.ijpharm.2023.123009

Cited by 7 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dash et al [ 112 ] synthesized chitosan-modified polylactic-co-glycolic acid (PLGA) atorvastatin–curcumin conjugate (AT-CU) nanoparticles for the management of atherosclerosis. Upon increasing the concentration of chitosan-modified PLGA AT-CU NPs, the particle size increased from 139.2 nm to 197.7 nm, the zeta potential ranged between 20.57 mV and 28.32 mV, and the drug encapsulation efficiency was enhanced from 71.81 to 90.57%.…”

Section: Herbal Bioactives Loaded Nanoformulations For Oral Deliverymentioning

confidence: 99%

Chitosan in Oral Drug Delivery Formulations: A Review

Sangnim,

Dheer,

Jangra

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Nanoformulations have become increasingly useful as drug delivery technologies in recent decades. As therapeutics, oral administration is the most common delivery method, although it is not always the most effective route because of challenges with swallowing, gastrointestinal discomfort, low solubility, and poor absorption. One of the most significant barriers that medications must overcome to exert a therapeutic effect is the impact of the first hepatic transit. Studies have shown that controlled-release systems using nanoparticles composed of biodegradable natural polymers significantly improve oral administration, which is why these materials have attracted significant attention. Chitosan possesses a wide variety of properties and functions in the pharmaceutical as well as healthcare industries. Drug encapsulation and transport within the body are two of its most important features. Moreover, chitosan can enhance drug efficacy by facilitating drug interaction with target cells. Based on its physicochemical properties, chitosan can potentially be synthesized into nanoparticles, and this review summarizes recent advances and applications of orally delivered chitosan nanoparticle interventions.

show abstract

Section: Herbal Bioactives Loaded Nanoformulations For Oral Deliverymentioning

confidence: 99%

Chitosan in Oral Drug Delivery Formulations: A Review

Sangnim,

Dheer,

Jangra

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Downregulating the intracellular transcription factors such as NF-kB, cyclooxygenase II, matrix metalloproteinase-9, activator protein 1, STAT3, and nitric oxide synthase has been remarkably induced apoptosis in different cell lines with curcumin treatment. [ 27 28 29 ] By inhibiting pyruvate kinase M2 (PKM2), curcumin has been found to offer a novel anticancer mechanism that lowers glucose absorption and lactate generation (the Warburg effect) in cancer cells. The PKM2 downregulation was accomplished by subduing the mammalian targets of rapamycin–hypoxia-inducible factor 1α.…”

Section: Role Of Natural Compounds In the Emerging Era Of Repurposingmentioning

confidence: 99%

Drug repurposing a compelling cancer strategy with bottomless opportunities: Recent advancements in computational methods and molecular mechanisms

Mohapatra,

Dash,

Yadav

et al. 2023

Indian J Pharmacol

View full text Add to dashboard Cite

Drug discovery has customarily focused on a de novo design approach, which is extremely expensive and takes several years to evolve before reaching the market. Discovering novel therapeutic benefits for the current drugs could contribute to new treatment alternatives for individuals with complex medical demands that are safe, inexpensive, and timely. In this consequence, when pharmaceutically yield and oncology drug efficacy appear to have hit a stalemate, drug repurposing is a fascinating method for improving cancer treatment. This review gathered about how in silico drug repurposing offers the opportunity to quickly increase the anticancer drug arsenal and, more importantly, overcome some of the limits of existing cancer therapies against both old and new therapeutic targets in oncology. The ancient nononcology compounds' innovative potential targets and important signaling pathways in cancer therapy are also discussed. This review also includes many plant-derived chemical compounds that have shown potential anticancer properties in recent years. Here, we have also tried to bring the spotlight on the new mechanisms to support clinical research, which may become increasingly essential in the future; at the same time, the unsolved or failed clinical trial study should be reinvestigated further based on the techniques and information provided. These encouraging findings, combined together, will through new insight on repurposing more non-oncology drugs for the treatment of cancer.

show abstract